Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vodafone Group Plc American Depositary Shares — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vodafone Group Plc American Depositary Shares trades at $15.51 (market cap $36.02B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 37× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vodafone Group Plc American Depositary Shares pays a 3.45% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vodafone Group Plc American Depositary Shares for 5 Days on average.
| MRVI | VOD | |
|---|---|---|
Market Cap | $972.90M | $36.02B |
Volume | 4,325,710 | 3,089,821 |
Sector | Health | Media |
52-Week High | $9.00 | $17.68 |
52-Week Low | $2.83 | $11.20 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $1.08B | $81.00B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VOD trades at $15.555, up 1.07% today, amid a bearish technical signal. The company reported a net loss of $4.17B for 2025, though revenue grew to $37.45B. Positive cash flow from operations of $15.37B and a low EV/EBITDA of 4.33 suggest underlying value. Recent news highlights Vodafone's strategic focus on 5G rollout and cost synergies in the UK, targeting £1 billion by 2032.
The outlook is mixed; analyst consensus leans buy (48%) with potential from operational improvements, but risks include persistent net losses, high debt, and competitive pressures. The stock's current valuation metrics (P/S 0.82, P/B 0.64) indicate it may be undervalued if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vodafone Group Plc American Depositary Shares
Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.
Read more on VOD →
